[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polysubstance-abuse\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polysubstance-abuse":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,77,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100518673","phase-3-motivational-interviewing-and-mindfulness-oriented-recovery-enhancement-100518673",false,"NCT06033599","Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement","Motivational Interviewing (MI) and Mindfulness-Oriented Recovery Enhancement (MORE) for Tobacco Dependence and Other Drug Use in Methadone Treatment","Inclusion Criteria:\n\n* English-speaking\n* Age ≥18\n* Currently on methadone; and 4) currently smoke cigarettes.\n\nExclusion Criteria:\n\n* Severe cognitive impairment (score \\>23 on Mini Mental Status Exam) or psychosis (positive SCID Psychotic Screen)\n* Suicidal risk (score ≥7 on Suicidal Behaviors Questionnaire)\n* Inability to attend or fully participate in intervention sessions or assessments\n* Previous formal mindfulness training (e.g., MBSR, MBRP) or MORE (from the R21 or R33\n* Currently taking smoking cessation pharmacotherapy or participating in smoking cessation counseling\n* Any contraindications for NRT\n* Currently or soon planning to be pregnant or breastfeeding.","ALL","18 Years",{"count":19,"type":20},420,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient outcomes related to the effectiveness of MORE decreasing opioid, tobacco, and other drug use.",[26,27,28],"Polysubstance Abuse","Opioid Use","Tobacco Use","RECRUITING","2026-04-27",{"date":32,"type":33},"2026-04-28","ACTUAL",{"date":35,"type":33},"2023-09-05",{"date":37,"type":20},"2028-06-30",{"name":39,"class":40},"Rutgers, The State University of New Jersey","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100628833","cedrn-opioid-registry-100628833","NCT07466784","CEDRN: Opioid Registry","Optimizing Outcomes for Patients Presenting to Emergency Departments With Opioid Poisoning","CEDRN OUD","Inclusion Criteria:\n\n1. All patients who arrive at the emergency department with the following emergency department discharge diagnosis:\n\n   * Percocet Overdose\n   * Oxycontin Overdose\n   * Oxycodone Overdose\n   * Opioid Overdose or Intoxication\n   * Methadone Overdose\n   * Heroin Overdose\n   * Fentanyl Overdose\n   * Codeine Overdose\n   * Carfentanil Overdose\n   * Opioid Withdrawal\n2. All patients who arrive at the emergency department who had the following medication ordered in the present visit or previous hospital visits in the past 2 years:\n\n   * Buprenorphine\n   * Buprenorphine-naloxone\n   * Methadone - Past ED or IP encounter\n   * Kadian\u002FMorphine long-acting\n   * Naloxone\n   * Naloxone kit\n3. All patients who arrive at the emergency department with the following impatient discharge diagnosis:\n\n   * Opioid use disorder (mild\u002Fmoderate\u002Fsevere, abuse\u002Fdependence), or opioid-related disorders\n   * Adverse effect, and poisoning by polysubstance use\n   * Opioid intoxication or withdrawal\n   * Intoxication or withdrawal (from any substance, including unspecified ones)\n   * Adverse effect, and poisoning by opioids, benzodiazepines, other antiepileptic and sedative-hypnotic drugs, and unspecified drugs\n   * Any psychoactive substance abuse resulting in intoxication, withdrawal, or any adverse effects",{"count":51,"type":20},7200,"1 Year","OBSERVATIONAL","Unregulated opioids remain a leading driver of preventable mortality and potential years of life lost in Canada. Emergency departments (EDs)-open 24\u002F7 and frequently accessed by people who use drugs-offer critical opportunities to reverse toxicity, mitigate harm, and initiate treatment. Yet, high quality evidence to guide ED care for patients with opioid poisoning and concomitant opioid dependence or opioid use disorder is limited. The investigators aim to establish a pan Canadian registry of patients presenting to EDs with opioid poisoning to generate timely, practice informing evidence. The investigators will create the Canadian Emergency Department Research Network (CEDRN) Opioid Registry across participating EDs nationwide. Using automated screening of electronic health records (EHRs), the investigators will identify consecutive patients of all ages with suspected or confirmed opioid poisoning at their index ED visit. The project's objectives are to establish a pan-Canadian registry of Emergency Department patients presenting with opioid poisoning, harmonize data collection across participating sites, describe variations in patient characteristics, clinical practice and outcomes, and derive a clinical decision rule to predict the risk of dying within 60 days. The expected outcomes include advancing healthcare delivery, improving patient and provider experiences, and enhancing population health and health system sustainability for individuals with opioid poisoning. This research is crucial for addressing the opioid crisis in Canada and has the potential to significantly impact patient care and outcomes.",[56,57,58,59,26],"Opioid Use Disorder","Opioid Abuse or Dependence","Opioid Withdrawal","Polysubstance Drug Use (Indiscriminate Drug Use)",[61,62,63,64,65,66],"Opioid use disorder","Opioid poisoning","CEDRN Opioid Registry","Opioid dependence","polysubstance abuse","polysubstance drug use","2026-03-09",{"date":69,"type":33},"2026-03-12",{"date":71,"type":33},"2025-07-24",{"date":73,"type":20},"2030-12-31",{"name":75,"class":40},"University of British Columbia",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":76},"100439729","phase-2-opioidbenzodiazepine-polydrug-abuse-aim-3-100439729","NCT05006079","Opioid\u002FBenzodiazepine Polydrug Abuse: Aim 3","Opioid\u002FBenzodiazepine Polydrug Abuse: Integrating Research on Mechanisms, Treatment and Policies - Study 3","MAP","Inclusion Criteria:\n\n* must self-report past 10-year experience taking opioid and sedative drugs (for therapeutic or non-therapeutic reasons), but not necessarily at the same time. As an alternative to the sedative drug exposure requirement, participants must have used alcohol on at least 3 separate days during the past month. Participants may have current mild- or moderate-severity Opioid Use Disorder or current mild- or moderate-severity Sedative Use Disorder;\n* must not be seeking treatment for their substance use problems;\n* must be in current good overall health\n\nExclusion Criteria:\n\n* meet DSM-5 criteria for current psychosis, bipolar disorder, or severe depression (i.e. severe psychiatric disorder);\n* meet DSM-5 criteria for severe substance use disorder for any substance (e.g. Sedative, Opioid, Alcohol);\n* past-month benzodiazepine or opioid prescription (which would suggest daily use, tolerance, or withdrawal upon cessation);\n* report of past-year any-drug overdose or suicide attempt\u002Fideation;\n* exhibit cognitive impairment (IQ \\\u003C 80 on the Shipley Institute of Living Scale);\n* neurological, cardiovascular, pulmonary, or systemic diseases (see specific exclusionary conditions under Protection of Human Subjects);\n* body mass index \\> 38 kg\u002Fm2;\n* females who are pregnant (urine), lactating or heterosexually active (self-report) and not using medically approved birth control;\n* treatment with methadone, buprenorphine or naltrexone;\n* past 30-day use of contraindicated medications;\n* alcohol-positive breath sample (\\>.02% breath alcohol concentration);\n* urine sample positive for methadone, cocaine, amphetamines, or barbiturates (\\\u003C300 ng\u002Fml)\n* intolerance of lactose","65 Years",{"count":87,"type":20},24,[89],"PHASE2","In this study, the investigators will measure affective, neurocognitive and behavioral outcomes related to chronic use of opioids and benzodiazepines (screening phase), and in response to the administration of the opioid morphine, the benzodiazepine alprazolam, morphine then alprazolam, alprazolam then morphine, morphine+alprazolam simultaneously, and placebo (laboratory pharmacology experiment). The latter will enable the investigators to assess the effects of an opioid alone, benzodiazepine alone, concurrent and simultaneous administration of opioid+benzodiazepine, relative to a placebo control.",[92,93,26],"Opioid Abuse","Benzodiazepine Abuse","2025-12-26",{"date":96,"type":33},"2025-12-30",{"date":98,"type":33},"2024-03-13",{"date":100,"type":20},"2026-12",{"name":102,"class":40},"Wayne State University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":121,"locationsCount":76},"100339170","opioidbenzodiazepine-polydrug-abuse-100339170","NCT03696017","Opioid\u002FBenzodiazepine Polydrug Abuse","Opioid\u002FBenzodiazepine Polydrug Abuse: Integrating Research on Mechanisms, Treatment and Policies","Inclusion Criteria:\n\n* Recently admitted and\u002For not clinically stable in treatment for Substance Use Disorder (SUD) in Wayne County\n* Using opioids, benzodiazepines (BZD), or BZD\u002Fopioid.\n\nExclusion Criteria:\n\n* Participants with current psychosis, bipolar disorder, or severe depression (i.e. severe psychiatric disorder)\n* Individuals with serious neurological disorders, e.g. brain tumor, history of stroke, history of traumatic brain injury w\u002F loss of consciousness\n* Cognitive impairment (IQ\\\u003C80)","70 Years",{"count":112,"type":20},120,"Benzodiazepine (BZD)\u002Fopioid polysubstance abuse (PSA) dramatically increases risks of overdose, disability and death; however, little is known about phenotypes that could be targeted to decrease this use and these associated risks.\n\nThe opioid abuse epidemic is generating unprecedented numbers of overdoses (OD) and deaths from prescribed and illegal sources (e.g. fentanyl combined with, or sold as, heroin). Yet, medical and epidemiological data suggest these adverse outcomes are not solely due to over-consumption of opioids.The FDA recognizes the health danger of BZD\u002Fopioid PSA, and issued labeling changes for prescribing BZDs and opioids. Impact of these changes is unclear and could be minimal if people obtain these substances illegally.\n\nBZD abuse can be harmful alone or combined with opioids, as BZDs: (a) contribute to OD\u002Fdeath e.g. 31% of opioid OD-related deaths from 1999 to 2011 were related to coincident BZD use, BZD co-use is dose-dependently related to mortality and rates of BZD OD deaths have sharply increased. (b) exacerbate progression and adverse outcomes of opioid abuse. and (c) worsen behavioral impairment from opioids, increase rates of falls and fractures, motor vehicle accidents, and sleep-disordered breathing.\n\nThere has been limited systematic research of BZD\u002Fopioid PSA. This is a major gap because BZD are often co-prescribed with opioids (in 33 to 50% of cases) and are easily obtained illegally.\n\nIn response to these problems, there is an urgent need to obtain population-level, clinical pharmacology, and mechanistic data to test our unified hypothesis of dual-deficit in affective\u002Fhedonic regulation.",[26],[92,116],"Benzodiazepine abuse",{"date":96,"type":33},{"date":119,"type":33},"2019-02-08",{"date":100,"type":20},{"name":102,"class":40}]